Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Marshall University Research Corporation has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a decentralized prosecution process. The use of 2 distinct art units suggests that the university's research in Biotechnology & Pharmaceuticals spans multiple specialized fields.
The busiest examiner, BRADLEY, CHRISTINA, is handling 1 busiest examiner pending action. Because the 2 pending office actions are divided among 2 distinct examiners, the university must manage separate interactions across 2 distinct art units. The 1 busiest examiner pending action represents a portion of the total 2 pending office actions, showing a split in examiner assignments. This distribution means that the 2 pending office actions are being reviewed independently, requiring the applicant to address the specific concerns of distinct examiners to advance their portfolio in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273158 | METHODS FOR DIAGNOSIS AND TREATMENT OF COVID-19 | LY, KRISTINA ELISABETH | 91d overdue |
| 18560230 | METHODS FOR INCREASING RED BLOOD CELL HALF-LIFE AND ASSOCIATED TREATMENT OF ANEMIA | BRADLEY, CHRISTINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273158 | METHODS FOR DIAGNOSIS AND TREATMENT OF COVID-19 | LY, KRISTINA ELISABETH | 91d overdue |
| 18560230 | METHODS FOR INCREASING RED BLOOD CELL HALF-LIFE AND ASSOCIATED TREATMENT OF ANEMIA | BRADLEY, CHRISTINA | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560230 | METHODS FOR INCREASING RED BLOOD CELL HALF-LIFE AND ASSOCIATED TREATMENT OF ANEMIA | BRADLEY, CHRISTINA | 1654 | §102§103§112Other | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18273158 | METHODS FOR DIAGNOSIS AND TREATMENT OF COVID-19 | LY, KRISTINA ELISABETH | 1671 | §101§102§103§112 | Non-Final OA | 91d overdue | Pending | Jul 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial